Australia’s largest company by market capitalisation, biotechnology manufacturer CSL has powered ahead in the first half of the financial year reporting a net profit after tax up 44 per...
Biotechnology giant CSL will spend more than $800 million building a new vaccine manufacturing plant at the Melbourne Airport Business Park, with operations expected to start in 2026. The...
Newsletter Signup
Subscribe to our newsletter for InnovationAus news delivered right to your inbox.